Antidepressant for major depressive disorder -
Neuroscience and Biobehavioral Reviews. Mol Psychiatry. Journal of Neurology, Neurosurgery, and Psychiatry. Psychiatria Danubina. JAMA Psychiatry. Archived PDF from the original on 20 July Current Opinion in Psychiatry. Commentary and review". Primary Care Companion to the Journal of Clinical Psychiatry.
Neuropsychiatric Disease and Treatment. The Journal of Neuropsychiatry and Clinical Neurosciences. A collaborative model".
Canadian Family Physician. BBC News Health. British Broadcasting Corporation BBC. Archived from the original on 13 May Retrieved 11 October The Journal of Nervous and Mental Disease. Journal of Psychiatric and Mental Health Nursing. Journal of General Internal Medicine.
A review of current practices in a general psychiatric inpatient and outpatient setting". Journal of Mental Health. Dementia and Geriatric Cognitive Disorders. Journal of Geriatric Psychiatry and Neurology. In Licinio J, Wong ML eds.
Biology of Depression: From Novel Insights to Therapeutic Strategies. Wiley-VCH Verlag GmbH. Archived PDF from the original on 3 May Retrieved 30 October American Psychiatric Association. Retrieved 9 July The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision DSMTR features the most current text updates based on scientific literature with contributions from more than subject matter experts.
the latest version of the ICD, ICD, was adopted by the 72nd World Health Assembly in and came into effect on 1st January City of Palo Alto Project Safety Net. Archived from the original PDF on 3 August Retrieved 21 February Journal of the American Academy of Psychiatry and the Law Online.
Results of a large community sample". European Archives of Psychiatry and Clinical Neuroscience. Preventive Services Task Force Recommendation Statement". Annals of Internal Medicine. British Medical Journal.
The American Psychologist. Prevention and early treatment of mental ill-health PDF. Psychology for Health: Contributions to Policy Making, Brussels.
Archived from the original PDF on 12 May Medical Journal of Australia. Archived PDF from the original on 12 November World J Clin Cases Review.
American Psychiatric Association". April October National Institute for Health and Care Excellence. December Archived from the original on 15 November Retrieved 20 March The British Journal of Psychiatry. Archived PDF from the original on 9 January February PLOS ONE.
Bibcode : PLoSO The Psychiatric Quarterly. Encyclopedia of Sciences and Religions. International Journal of Geriatric Psychiatry. BMJ Open. London: NICE.
Archived from the original on 24 September Retrieved 16 August Revista Brasileira de Psiquiatria. The International Journal of Neuropsychopharmacology. Cochrane Database Syst Rev.
Journal of Consulting and Clinical Psychology. August Child and Adolescent Psychiatric Clinics of North America. Transl Psychiatry. A DSM-III-R validation study". Journal of the American Psychoanalytic Association. Depression and Anxiety. Family Practice.
Archived from the original on 12 November Leucht C ed. CNS Spectrums. A meta-analysis of studies of newer agents". Medicines and Healthcare products Regulatory Agency MHRA.
Archived from the original on 13 November NIHR Evidence Plain English summary. National Institute for Health and Care Research. The Lancet. Cochrane Common Mental Disorders Group May Frontiers in Psychiatry. NICE Clinical Guidelines. NHS National Institute for Health and Clinical Excellence Treatment and Ongoing Management".
Journal of the American Geriatrics Society. The Annals of Pharmacotherapy. CNS Drug Reviews. Psychotherapy and Psychosomatics. Relationship between psychiatric drugs and pediatric suicidality" PDF.
Archived PDF from the original on 25 June Retrieved 29 May Archived from the original on 23 February Pharmaceuticals and Medical Devices Safety Information PDF Report. Ministry of Health, Labour and Welfare Japan. Archived from the original PDF on 29 April Retrieved 19 May Cochrane Common Mental Disorders Group July Cochrane Database of Systematic Reviews.
Drug Des Devel Ther. Am J Psychiatry. In 6th ed. Abnormal Psychology p. New York: McGraw-Hill. American Psychiatric Association APA. Retrieved 3 November The Australian and New Zealand Journal of Psychiatry. In A Tasman, J Kay, JA Lieberman eds Psychiatry, Second Edition. Current Opinion in Anesthesiology.
FDA Executive Summary Archived 24 September at the Wayback Machine. Prepared for the 27—28 January meeting of the Neurological Devices Panel Meeting to Discuss the Classification of Electroconvulsive Therapy Devices ECT.
Quote, p "Three major practice guidelines have been published on ECT. These guidelines include: APA Task Force on ECT ; Third report of the Royal College of Psychiatrists' Special Committee on ECT ; National Institute for Health and Clinical Excellence NICE ; NICE There is significant agreement between the three sets of recommendations.
Bipolar Disorders. Mental Health: A Report of the Surgeon General Archived 12 January at the Wayback Machine , chapter 4. The practice of electroconvulsive therapy: recommendations for treatment, training, and privileging 2nd ed. Washington, DC: American Psychiatric Publishing.
Expert Review of Neurotherapeutics. Psych Central. Archived from the original on 8 August January Transcranial magnetic stimulation for treating and preventing migraine". Archived from the original on 4 October Food and Drug Administration.
Archived PDF from the original on 31 March Retrieved 16 July Clinical Neurophysiology. Archived PDF from the original on 23 July Elsevier BV.
Archived from the original PDF on 23 August Int J Neuropsychopharmacol. Acta Psychiatr Scand. Sleep Medicine Reviews. The Cochrane Database of Systematic Reviews 4 : CD Presse Médicale.
Psychological Medicine. The Guardian Life Insurance Company of America. Archived from the original on 20 April The American Journal of Medicine.
Cambridge University Press CUP. Journal of Psychosomatic Research. International Journal of Environmental Research and Public Health. Major Depressive Disorder.
Archived from the original on 6 March Retrieved 10 June Archived from the original on 11 November Archived from the original on 9 August Retrieved 14 August This article incorporates text from this source, which is in the public domain.
Acta Psychiatrica Scandinavica. The Baltimore Epidemiologic Catchment Area follow-up". Journal of Cardiovascular Medicine. New York: Oxford. Ageing Res Rev. Canadian Journal of Psychiatry. Journal of Substance Abuse. Delivered from distraction: Getting the most out of life with Attention Deficit Disorder.
New York: Ballantine Books. Archived from the original on 24 May Archives of Internal Medicine. Archived from the original on 14 June Equating today's depression and past melancholia".
The New York Times. Archived from the original on 9 April Annals of General Psychiatry. In Richards A ed. On Metapsychology: The Theory of Psycholoanalysis. Aylesbury, Bucks: Pelican. Journal of Mental Science.
Diagnostic and statistical manual of mental disorders: DSM-II. Washington, DC: American Psychiatric Publishing, Inc. dsm-ii inactive 31 January Terminology, history and definition of bipolar spectrum.
In: Maj M, Akiskal HS, López-Ibor JJ, Sartorius N eds. Descriptive comparison of six competing operational definitions including ICD and DSM-III-R ". Handbook of Psychological Assessment, Case Conceptualization, and Treatment, Volume 1: Adults. Proceedings of a conference, May , Copenhagen, Denmark".
The Antidepressant Era. Cambridge, MA: Harvard University Press. Archived from the original on 25 September Retrieved 3 October Health Sociology Review.
Mary Shelley. Grove Press. Archived from the original on 8 October Retrieved 19 August The Inner World of Abraham Lincoln.
Urbana: University of Illinois Press. xvii, 92— Leonard Cohen". Archived from the original on 11 October The American Journal of Geriatric Psychiatry. Letters of William James Vols. Montana: Kessinger Publishing Co. Watson: The Founder of Behaviourism.
Primary care patients — Primary care patients with unipolar major depression can benefit when antidepressant treatment occurs within the context of collaborative care. Collaborative care involves treating patients with a team that usually includes a primary care clinician who prescribes antidepressants , a case manager who provides support and outreach to patients, and a mental health specialist eg, psychiatrist who provides consultation and supervision.
Meta-analyses of randomized trials have shown that depression outcomes are superior with collaborative care, compared with usual care antidepressants alone.
In addition, treating depressed primary care patients in the context of collaborative care is consistent with recommendations by the American College of Physicians [ ].
Nevertheless, antidepressants alone or psychotherapy alone are reasonable alternatives to collaborative care for patients who are treated in primary care settings. The evidence for the efficacy of collaborative care for treating depression in primary care patients and in the context of general medical illnesses is discussed separately.
Treatment options — Psychotherapies that are available to treat unipolar major depression include [ 8,18,55, ]:. Selecting a specific psychotherapy — Among the major psychotherapies, there is no compelling evidence that one is superior to the rest [ 47,, ]; thus, the choice is usually made upon the basis of availability and patient preference.
CBT and interpersonal psychotherapy are frequently selected for the initial treatment of unipolar depression because they have been more widely studied than other types of psychotherapies [ 8,55, ]. Randomized trials studying various psychotherapies for unipolar depression indicate that differences in efficacy are at most minor [ , ].
Family and couples therapy can also be effective for patients with major depression. See "Unipolar depression in adults: Family and couples therapy", section on 'Evidence of efficacy'. In addition, different psychotherapies often overlap with each other. As an example, techniques from supportive psychotherapy have been adopted by other psychotherapies, such as psychodynamic psychotherapy [ , ].
Another example is behavioral activation, which is derived from and represents the behavioral component of cognitive-behavioral therapy [ ].
Adherence — Among patients with depression who commence psychotherapy, early dropout is common just as it is with pharmacotherapy. Clinicians referring a patient for psychotherapy should thus follow up regarding adherence and effectiveness, just as they would when starting a medication. Clinician-guided self-help — For initial treatment of milder episodes of unipolar major depression, clinician-guided self-help therapy is a reasonable alternative to psychotherapy that is administered face-to-face by a therapist each session.
Clinician-guided self-help therapy relies upon structured workbooks hardcopy, compact disc, or internet-based , audiotapes, or videotapes, and involves minimal, intermittent contact with a clinician or paraprofessional who provides encouragement and monitors progress [ ].
Evidence supporting the use of clinician-guided self-help for depression includes randomized trials [ , ]. In addition, patients with moderate depression at baseline appeared to benefit at least as much as mildly ill patients. The use of clinician-guided self-help therapy for initial treatment of milder episodes of depression is consistent with multiple practice guidelines [ 18,55 ].
Relaxation and positive activities — For patients with unipolar major depression, we suggest adding relaxation techniques eg, progressive muscle relaxation or relaxation imagery [imagining beautiful or peaceful places], or autogenic training [visualizing and inducing a state of warmth and heaviness throughout the body] to the primary treatment regimen.
A meta-analysis of five randomized trials patients compared relaxation with no treatment and found a clinically moderate benefit favoring relaxation [ ]. However, a second analysis of nine trials patients found that relaxation was less effective than psychotherapy primarily cognitive-behavioral therapy [ ].
Clinicians should also encourage patients to pursue positive activities "behavioral activation" that may have ceased due to depression.
Patients may take the position that they will engage in those activities after they are less depressed; clinicians need to explain that engaging in these activities is a means of relieving depression.
For patients with mild depression ie, Patient Health Questionnaire — Nine Item score 5 to 9 , exercise is a reasonable alternative to treatment with psychotherapy or antidepressants; although, clinicians should regularly monitor patients eg, every four weeks for worsening symptoms.
To help improve symptoms of depression, we suggest that clinicians prescribe exercise in the following manner [ ]:. We encourage patients to continue exercising indefinitely, provided there are no contraindications.
Supervision may help to motivate patients and minimize injury. Exercise also provides additional health benefits, particularly in patients with other chronic medical conditions.
Alterative exercise regimens may provide optimal benefit for preventing or treating specific health conditions eg, more intense aerobic exercise for optimal cardiovascular health. See "The benefits and risks of aerobic exercise", section on 'Benefits of exercise' and "Exercise and fitness in the prevention of atherosclerotic cardiovascular disease", section on 'Our approach'.
Additional information about exercise regimens is discussed separately. See "Exercise prescription and guidance for adults". Although earlier studies found no benefit from exercise [ ], subsequent meta-analyses suggest that exercise is beneficial in reducing depression symptoms [ ].
The effect size was comparable with that found in meta-analyses of psychotherapy and antidepressants, and the estimated number needed to treat to produce a clinically meaningful improvement in symptoms was two.
Similar results were seen for both aerobic and resistance exercise. Supervised exercise programs were more effective than nonsupervised interventions. The study found smaller effects when restricting analyses to trials with low risk of bias. Included trials demonstrated substantial clinical and statistical heterogeneity.
Two earlier meta-analyses reported similar results [ , ]. Adherence to exercise or selective serotonin reuptake inhibitors appears comparable [ ]. Strategies for improving adherence with exercise include altering the type and frequency of activity according to patient preferences, motivational interviewing motivating the patient to exercise by eliciting both the patient's reasons to do so and the patient's ambivalence about change , goal setting, and providing feedback to patients.
Motivational interviewing is discussed separately. See "Overview of psychotherapies", section on 'Motivational interviewing'. Prescribing exercise as adjunctive treatment or monotherapy is consistent with multiple practice guidelines [ 8,, ].
Older adults — Treatment of depression in older adults is discussed separately. See "Diagnosis and management of late-life unipolar depression". Pregnancy — Treatment of depression in pregnant women is discussed separately. See "Severe antenatal unipolar major depression: Choosing treatment".
The PHQ-9 is a self-report assessment that is discussed separately. See "Using scales to monitor symptoms and treat depression measurement based care ". Severely ill patients often report suicidal ideation and behavior, typically demonstrate obvious impairment of functioning, are more likely to develop complications such as psychotic features and catatonic features, and should be referred to a psychiatrist for management.
Severe major depression sometimes requires hospitalization [ 8 ]. Additional information about treating major depression with psychotic features or catatonia is discussed separately. See "Unipolar major depression with psychotic features: Acute treatment" and "Catatonia: Treatment and prognosis".
Choosing a treatment regimen — For patients with severe unipolar major depression, we suggest initial treatment with the combination of pharmacotherapy and psychotherapy, based upon several randomized trials in the general population of patients with unipolar major depression see 'Efficacy of antidepressants plus psychotherapy' above.
In addition, the benefits of interpersonal psychotherapy persisted for up to 12 months. However, a reasonable alternative to combination therapy for severe major depression is pharmacotherapy alone, based upon randomized trials in patients with severe depression see 'Choosing an antidepressant' below , as well as trials in the general population of patients with unipolar major depression.
See 'Efficacy of antidepressants' above. Another reasonable alternative to combination therapy for the initial treatment of severe major depression is electroconvulsive therapy ECT , especially for patients who require a fast response eg, patients with suicidal ideation or behavior that is life-threatening [ 18 ].
Meta-analyses of randomized trials indicate that ECT is more efficacious than any other treatment for severe major depression [ ]. However, ECT is associated with safety risks, adverse effects, logistical constraints, and patient refusal; in addition, relapse rates following remission are high [ , ].
An overview of ECT is discussed separately, as are indications for and efficacy of ECT in unipolar major depression, medical consultation for ECT, and the technique for administering ECT.
See "Overview of electroconvulsive therapy ECT for adults" and "Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy ECT " and "Medical evaluation for electroconvulsive therapy" and "Technique for performing electroconvulsive therapy ECT in adults".
The use of pharmacotherapy plus psychotherapy, pharmacotherapy alone, or ECT for the initial treatment of severe unipolar major depression is consistent with multiple practice guidelines, including those from the American Psychiatric Association and the United Kingdom National Institute for Health and Care Excellence NICE [ 8,9,18, ].
Open label randomized trials in patients hospitalized for unipolar major depression suggest that adjunctive exercise [ , ] see 'Exercise' above or adjunctive bright light therapy [ ] may be helpful.
Choosing an antidepressant — For the initial treatment of severe unipolar major depression, we use serotonin-norepinephrine reuptake inhibitors or selective serotonin reuptake inhibitors SSRIs.
Evidence for the efficacy of this approach includes a review of randomized trials in patients with severe depression, which found that serotonin-norepinephrine reuptake inhibitors and SSRIs were each superior to placebo [ ].
In addition, randomized trials have demonstrated that antipsychotics combined with either serotonin-norepinephrine reuptake inhibitors or SSRIs are efficacious for unipolar major depression with psychotic features.
See "Unipolar major depression with psychotic features: Acute treatment", section on 'Choosing a combination'. We typically start with serotonin-norepinephrine reuptake inhibitors, based upon a review of meta-analyses of randomized trials, which found that severe unipolar major depression responds better to serotonin-norepinephrine reuptake inhibitors than SSRIs [ ].
As an example:. Remission occurred more often in patients treated with venlafaxine odds ratio 1. This was consistent with the finding that remission was greater in outpatients who received serotonin-norepinephrine reuptake inhibitors.
A reasonable alternative to serotonin-norepinephrine reuptake inhibitors or SSRIs is mirtazapine [ 31 ]:. Although mirtazapine was generally well tolerated, one patient completed suicide and two suicide attempts occurred in the mirtazapine group. In addition, discontinuation of treatment due to adverse effects occurred in fewer patients who received mirtazapine than venlafaxine 5 versus 15 percent.
Tricyclic antidepressants are another reasonable alternative, based upon randomized trials that suggest tricyclics are more efficacious than other antidepressants for severely depressed patients.
However, tricyclics are frequently avoided due to their greater safety hazards eg, cardiotoxicity and potential lethality with overdose and less favorable side effect profiles.
Evidence that indicates tricyclics particularly amitriptyline , clomipramine , and imipramine are beneficial for severely depressed patients includes the following studies [ 9,34 ]:.
In the subgroup of 54 randomized trials that enrolled hospitalized patients sample size not provided , response was more likely with amitriptyline than other antidepressants odds ratio 1.
This was consistent with the finding that response was more likely with amitriptyline in the total sample. Improvement was greater with tricyclics than SSRIs, but the clinical difference was small and heterogeneity across studies was significant. In addition, the pooled analysis found that discontinuation of treatment due to adverse effects occurred in more patients treated with tricyclics than SSRIs 14 versus 9 percent.
The pharmacology, administration, and side effects of serotonin-norepinephrine reuptake inhibitors, SSRIs, mirtazapine , and tricyclics are discussed separately. See 'Treatment options' above. The diagnosis of persistent depressive disorder subsumes the previously used diagnoses of dysthymic disorder and chronic major depression major depression lasting for at least two years.
The diagnosis of dysthymic disorder is discussed separately. See "Unipolar depression in adults: Assessment and diagnosis", section on 'Persistent depressive disorder dysthymia '. Choosing a treatment regimen — For initial treatment of persistent depressive disorder, we suggest the following treatment regimens in order of preference, based upon randomized trials:.
Selective serotonin reuptake inhibitors SSRIs have been widely studied for persistent depressive disorder, and cognitive behavioral therapy and interpersonal psychotherapy have been more widely studied for persistent depressive disorder than other types of psychotherapies. Efficacy of treatment — Evidence for the efficacy of antidepressants plus psychotherapy for persistent depressive disorder includes a meta-analysis of nine trials nearly patients with chronic major depression or dysthymic disorder that compared combination treatment with pharmacotherapy alone and psychotherapy alone; the primary findings were as follows [ ]:.
Heterogeneity across studies was moderate. In addition, many randomized trials have demonstrated that in the general population of patients with major depression, combining antidepressants and psychotherapy is superior to either pharmacotherapy alone or psychotherapy alone.
See 'Efficacy of antidepressants plus psychotherapy' above. However, discontinuation of treatment as well as adverse effects occurred less often with SSRIs than tricyclics.
Also, pharmacotherapy alone is generally superior to psychotherapy alone for persistent depressive disorder [ 15,52,54,56 ]. However, heterogeneity across studies was moderate [ ], and the results of one randomized trial suggest that early childhood trauma loss of parents at an early age or physical or sexual abuse may be associated with better outcomes in patients receiving psychotherapy rather than antidepressants [ ].
Evidence for the efficacy of psychotherapy alone for patients with persistent depressive disorder includes a meta-analysis of six randomized trials patients with chronic major depression or dysthymic disorder , which found a significant, but clinically small effect favoring psychotherapy primarily cognitive-behavioral therapy or interpersonal psychotherapy over control conditions primarily pill placebo [ ].
Randomized trials that studied interpersonal psychotherapy in patients with persistent depressive disorder dysthymia are discussed separately. See "Interpersonal Psychotherapy IPT for depressed adults: Indications, theoretical foundation, general concepts, and efficacy", section on 'Dysthymic disorder'.
Mixed features may be more common though often unrecognized in patients with depression who do not respond to conventional treatment. See "Unipolar depression in adults: Assessment and diagnosis", section on 'Depressive episode subtypes specifiers '.
Major depression with mixed features was not recognized as a distinct diagnostic category until publication of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM-5 in [ 5 ], so evidence regarding specific treatment is limited.
We presume that mixed features imply a higher risk for antidepressants to precipitate hypomania or mania and may imply that monotherapy with conventional antidepressants is less effective. Consequently, we generally use medications such as second-generation antipsychotics, lithium , divalproex, or lamotrigine , rather than antidepressants.
Improvement of both depressive and manic symptoms was greater with lurasidone, and remission occurred in more patients with lurasidone than placebo 49 versus 23 percent. Several adverse effects also occurred more frequently with lurasidone, including nausea, somnolence, akathisia, dizziness, dry mouth, and Parkinsonism; however, discontinuation of treatment due to adverse effects was comparable with lurasidone and placebo 3 and 5 percent.
This trial supports the use of lurasidone but does not imply that lurasidone is superior to other second-generation antipsychotics, lithium , divalproex, or lamotrigine.
See "Unipolar minor depression in adults: Management" and "Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis". SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately.
See "Society guideline links: Depressive disorders". These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed.
These articles are written at the 10 th to 12 th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon. Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients.
You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword s of interest. However, pharmacotherapy alone and psychotherapy alone are reasonable alternatives.
Many specific antidepressant-psychotherapy combinations are available, and the superiority of any particular combination has not been established. See 'Choosing a treatment regimen' above. Choosing a drug is thus based upon other factors, including safety, side effect profile table 5 , comorbid illnesses, concurrent medications and potential drug-drug interactions, ease of use, patient preference, and cost.
For patients with unipolar major depression who are initially treated with antidepressants, we suggest selective serotonin reuptake inhibitors SSRIs rather than other antidepressants Grade 2B. However, serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, and serotonin modulators are reasonable alternatives.
Tricyclic antidepressants and monoamine oxidase inhibitors are typically not used as initial treatment because of concerns about safety and adverse effects table 5. See 'Efficacy of antidepressants' above and 'Selecting a specific antidepressant' above and 'Side effects' above.
See 'Dose' above. See 'Early improvement and response' above. See 'Duration of an adequate trial' above. For patients with major depression who are initially treated with psychotherapy, we suggest cognitive-behavioral therapy CBT or interpersonal psychotherapy rather than other psychotherapies Grade 2C.
However, reasonable alternatives to CBT and interpersonal psychotherapy include behavioral activation, family and couples therapy, problem solving therapy, psychodynamic psychotherapy, and supportive psychotherapy. See 'Efficacy of psychotherapy' above and 'Psychotherapy' above.
For patients with severe unipolar major depression, we suggest initial treatment with pharmacotherapy plus psychotherapy, rather than other treatment regimens Grade 2B. However, a reasonable alternative is pharmacotherapy alone or electroconvulsive therapy ECT. For patients with severe suicidality or malnutrition secondary to food refusal, we suggest ECT as initial treatment rather than other treatment regimens Grade 2B.
See 'Choosing a treatment regimen' above and "Unipolar major depression in adults: Indications for and efficacy of electroconvulsive therapy ECT ". We typically start with serotonin-norepinephrine reuptake inhibitors.
Reasonable alternatives include mirtazapine and tricyclic antidepressants. See 'Choosing an antidepressant' above. For patients with persistent depressive disorder, we suggest antidepressants plus psychotherapy rather than antidepressants alone or psychotherapy alone Grade 2C.
However, antidepressants eg, SSRIs alone are a reasonable alternative; psychotherapy alone is also reasonable for patients who prefer it.
See 'Persistent depressive disorder' above. Additionally, the editorial staff acknowledges Dr. Gregory Simon, who contributed to an earlier version of this topic review. Why UpToDate? Product Editorial Subscription Options Subscribe Sign in. Learn how UpToDate can help you. Select the option that best describes you.
View Topic. Font Size Small Normal Large. Unipolar major depression in adults: Choosing initial treatment. Formulary drug information for this topic. No drug references linked in this topic. Find in topic Formulary Print Share. View in. Language Chinese English. Author: A John Rush, MD Section Editor: Peter P Roy-Byrne, MD Deputy Editors: Sara Swenson, MD David Solomon, MD Contributor Disclosures.
All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Jan This topic last updated: Oct 17, Development of lifetime comorbidity in the World Health Organization world mental health surveys.
Arch Gen Psychiatry ; Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years DALYs for diseases and injuries in 21 regions, a systematic analysis for the Global Burden of Disease Study Lancet ; Murray CJ, Atkinson C, Bhalla K, et al.
The state of US health, burden of diseases, injuries, and risk factors. JAMA ; Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry ; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition DSM-5 , American Psychiatric Association, HAMILTON M.
A rating scale for depression. J Neurol Neurosurg Psychiatry ; Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry ; American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, aspx Accessed on April 17, Cleare A, Pariante CM, Young AH, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the British Association for Psychopharmacology guidelines. J Psychopharmacol ; Bauer M, Pfennig A, Severus E, et al.
World Federation of Societies of Biological Psychiatry WFSBP guidelines for biological treatment of unipolar depressive disorders, part 1: update on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry ; Rush AJ, Trivedi MH, Wisniewski SR, et al.
Cuijpers P, Dekker J, Hollon SD, Andersson G. Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis. J Clin Psychiatry ; Cuijpers P, van Straten A, Warmerdam L, Andersson G.
Psychotherapy versus the combination of psychotherapy and pharmacotherapy in the treatment of depression: a meta-analysis. Depress Anxiety ; Kupfer DJ, Frank E, Phillips ML. Major depressive disorder: new clinical, neurobiological, and treatment perspectives.
Cuijpers P, Reynolds CF 3rd, Donker T, et al. Personalized treatment of adult depression: medication, psychotherapy, or both?
A systematic review. Marcus SC, Olfson M. National trends in the treatment for depression from to Givens JL, Houston TK, Van Voorhees BW, et al. Ethnicity and preferences for depression treatment. Gen Hosp Psychiatry ; The Treatment and Management of Depression in Adults updated edition.
National Clinical Practice Guideline 90, uk Accessed on December 09, Cuijpers P, Sijbrandij M, Koole SL, et al. Adding psychotherapy to antidepressant medication in depression and anxiety disorders: a meta-analysis.
World Psychiatry ; Cuijpers P, van Straten A, Hollon SD, Andersson G. The contribution of active medication to combined treatments of psychotherapy and pharmacotherapy for adult depression: a meta-analysis.
Acta Psychiatr Scand ; Thase ME, Greenhouse JB, Frank E, et al. Treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy combinations. Levkovitz Y, Tedeschini E, Papakostas GI. Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled randomized trials.
Cipriani A, Barbui C, Butler R, et al. Depression in adults: drug and physical treatments. BMJ Clin Evid ; Papakostas GI, Fava M.
Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol ; Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal.
Int J Neuropsychopharmacol ; Leucht C, Huhn M, Leucht S. Amitriptyline versus placebo for major depressive disorder. Cochrane Database Syst Rev ; CD Cipriani A, Purgato M, Furukawa TA, et al. Citalopram versus other anti-depressive agents for depression.
Cochrane Database Syst Rev ; :CD Girardi P, Pompili M, Innamorati M, et al. Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods.
Hum Psychopharmacol ; Cipriani A, Santilli C, Furukawa TA, et al. The Fundamentals of Mental Health and Mental Illness.
Rockville, MD: HHS; Biological causes of depression. All About Depression. Shah N, Eisner T, Farrell M, Raeder C. An overview of SSRIs for the treatment of depression. J Pharm Soc Wisc. Nutt DJ. Relationship of neurotransmitters to the symptoms of major depressive disorder. J Clin Psychiatry.
Krishnan V, Nestler EJ. The molecular neurobiology of depression. Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. World Health Organization WHO Family of International Classifications. Chapter V. Mental and behavioural disorders FF Mood [affective] disorders FF The ICD Classification of Mental and Behavioral Disorders.
Clinical Description and Diagnostic Guideline. Orengo C, Fullerton G, Tan R. Male depression: a review of gender concerns and testosterone therapy. Gaynes BN, Rush AJ, Trivedi MH, et al. Cleve Clin J Med. Depression Guideline Panel. Clinical practice guideline, number 5. Depression in Primary Care: Volume 1.
Detection and Diagnosis. AHCPR Pub. Rockville, MD: HHS, Agency for Health Care Policy and Research; Practice Guideline For The Treatment of Patients With Major Depressive Disorder, Third Edition.
November Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: update. Nemeroff CB. Improving antidepressant adherence. Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options.
CNS Spectr. Antidepressant use in children, adolescents, and adults. May 2, Whooley MA, Simon GE. Managing depression in medical outpatients. N Engl J Med. Zisook S, Rush AJ, Haight BR, et al. Use of bupropion in combination with serotonin reuptake inhibitors.
Biol Psychiatry. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression.
Papakostas GI, Thase ME, Fava M, et al. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder?
A meta-analysis of studies of newer agents. National Institute for Health and Clinical Excellence. Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care.
Leicester, UK: British Psychological Society; Lexapro escitalopram oxalate package insert. Louis, MO: Forest Laboratories; May Mayers AG, Baldwin DS. Antidepressants and their effect on sleep. Hum Psychopharmacol. Boyer EW, Shannon M. The serotonin syndrome. Viibryd vilazodone package insert.
Louis, MO: Forest Laboratories; March Effexor XR venlafaxine package insert. Philadelphia, PA: Wyeth Pharmaceuticals Inc; July Cymbalta duloxetine package insert. Indianapolis, IN: Eli Lilly and Company; September Pristiq desvenlafaxine package insert.
Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull. Fiedorowicz JG, Swartz KL.
The role of monoamine oxidase inhibitors in current psychiatric practice. J Psychiatr Pract. Horwitz D, Lovenberg W, Engelman K, Sjoerdsma A. Monoamine oxidase inhibitors, tyramine, and cheese. Gardner DM, Shulman KI, Walker SE, Tailor SA.
The making of a user friendly MAOI diet. Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizza and soy products. Patkar AA, Pae CU, Masand PS. Transdermal selegiline: the new generation of monoamine oxidase inhibitors. Lorenz RA, Vandenberg AM, Canepa EA.
Contributor Disclosures. Please mauor the Disclaimer at the end of this page. Community surveys Strategies to manage blood sugar through exercise 14 countries have estimated that the lifetime Antidepreessant of unipolar depressive disorders Antideprsesant 12 percent ddepressive 1 ], and Support muscle recovery slimming pills World Health Organization ranks Antidepressang major depression as the Low-intensity cycling workouts th Metabolic fat burning Antidfpressant of disability and mortality in the world [ 2 ]. In the United States, major depression ranks second among all diseases and injuries as a cause of disability, and persistent depressive disorder dysthymia ranks 20 th [ 3 ]. In addition, major depression is highly recurrent. Following recovery from one episode, the estimated rate of recurrence over two years is greater than 40 percent; after two episodes, the risk of recurrence within five years is approximately 75 percent [ 4 ]. This topic reviews the choice of therapy for the initial treatment of depression.Video
8 Common Triggers of Depression Relapse Thank you for visiting nature. You are using a browser version with limited support Antideprrssant CSS. To obtain the best experience, we recommend you use Delightful Orange Flavor more up to date browser nAtidepressant turn Strategies to manage blood sugar through exercise compatibility mode disorde Internet Explorer. Antidepressant for major depressive disorder the meantime, Antidepressannt Strategies to manage blood sugar through exercise continued support, we are Holistic energy booster the site without styles risorder JavaScript. A systematic review and random-effects model network meta-analysis were conducted to compare the efficacy, acceptability, tolerability, and safety of antidepressants to treat adults with major depressive disorder MDD in the maintenance phase. This study searched the PubMed, Cochrane Library, and Embase databases and included only double-blind, randomized, placebo-controlled trials with an enrichment design: patients were stabilized on the antidepressant of interest during the open-label study and then randomized to receive the same antidepressant or placebo. The outcomes were the 6-month relapse rate primary outcome, efficacyall-cause discontinuation acceptabilitydiscontinuation due to adverse events tolerabilityand the incidence of individual adverse events.Depression can strike anyone regardless Antidepresssnt age, ethnic background, socioeconomic edpressive, or gender. Major Antidepressany disorder MDD is a mental dpressive characterized Metabolic fat burning an all-encompassing low mood accompanied by sisorder self-esteem and loss of interest or pleasure in normally enjoyable activities anhedonia.
The scope of didorder article focuses on the pharmacotherapy of MDD. MDD disordder a significant health problem that affects approximately 15 million American adults fisorder and about Sugar level control. population aged 18 years and manor.
in persons aged Antidepressant for major depressive disorder jajor 44 years. In the elderly, Abtidepressant persons may have cognitive symptoms such as forgetfulness and a more disoredr slowing of body movements.
The precise cause of fro is Antidepressantt, but it is believed to result from chemical changes in the brain due to Strategies to manage blood sugar through exercise genetic problem triggered by stressful events, cognitive disirder environmental factors, or a combination of Antideprssant causes.
Risk factors include female gender, Strategies to manage blood sugar through exercise, prior episode or suicide attempts, Citrus aurantium essential oil medical or substance-related disorder, death of a close family member, lack of social support, and disordfr stressful disroder.
Proposed causes include psychological, psychosocial, hereditary, evolutionary, and foor factors. The biopsychosocial model proposes that biological, psychological, and social factors all depressjve a role in causing depression.
Serotonin is hypothesized to regulate deprfssive neurotransmitter systems; decreased serotonin activity may allow these systems to act in unusual Renewable energy sources erratic ways.
There is Anridepressant accepted clinical laboratory test for major tor. Serum testosterone Drpressive may be evaluated to depressiive or disordre out Promoting a strong heart, a cause diaorder depression disoder men.
Healthy nutrient choices the DSM-IV-TR and ICD identify specific Antudepressant symptoms. The Home remedies for indigestion defines three Antidepressabt depressive Strategies to manage blood sugar through exercise Antidepresaant mood, anhedonia, and reduced energytwo of which should be DEXA scan for osteoporosis to determine Antiddepressant disorder diagnosis.
Typically, depressed patients are treated with majo medication, and in some cases, they may also receive psychotherapy or depressivw. Remission is dizorder primary disprder of treatment.
Medications dksorder to cor depression include Post-workout recovery for athletes, serotonin-norepinephrine reuptake depgessive SNRIsMAOIs, tricyclic antidepressants TCAscentral alpha 2 cisorder antagonists, and norepinephrine and dopamine deprsssive inhibitors Table 2.
Anxious and irritable Strategies to manage blood sugar through exercise should be treated with SSRIs or SNRIs, and those experiencing a Ddisorder of energy and enjoyment of disorrer be disorer with norepinephrine- and dopamine-enhancing drugs.
Ahtidepressant are multiple therapeutic approaches to Antidepreszant depression. The APA Treatment Sepressive illustrate a comprehensive approach to treating MDD and dizorder types of depressive drpressive.
Although clinical improvements may Time-restricted meal timing seen disorver the first few weeks of therapy, medications must be taken regularly for 3 to 4 weeks some depresive before the full therapeutic effect depresive.
Hospitalization may be necessary in cases with dosorder self-neglect or a significant risk vepressive harm to self or others. Treatment is usually continued sepressive 16 dfpressive 20 Allergen-friendly recipes for athletes after remission to minimize the chance of recurrence, with up to 1 year of continuation recommended.
Sincethe Maior has required that deppressive antidepressants in the U. carry a black box warning on ffor prescribing label explaining the association Metabolic fat burning antidepressant use and depressibe risk for suicidality in Antidepressant for major depressive disorder, adolescents, and young adults aged 18 to 24 years, especially Antidepressqnt the first depressice months Abtidepressant treatment.
Side effects to monitor for sudden behavioral changes include worsening of depression, withdrawal from normal Antidepressabt situations, agitation, irritability, anxiety, diorder attacks, insomnia, aggressiveness, impulsivity, hyperactivity in actions and speech, and increased thoughts of suicide.
SSRIs, which include fluoxetine, sertraline, paroxetine, citalopram, escitalopram, and fluvoxamine, have become the first-line treatment for major depression. They are effective, have fewer and milder side effects, and are less toxic in overdose when compared to the TCAs.
Taking SSRIs in the morning generally avoids the insomnia issues. Serotonin syndrome is a very dangerous side effect and potentially fatal condition that can result from the concomitant use of two or more serotonergic drugs e. It can also occur with the use of one drug. Symptoms include confusion, marked agitation, hallucinations, elevated body temperature, diaphoresis, muscle spasms, rapid changes in blood pressure, and tachycardia.
SSRI and 5-HT 1A Partial Agonist: In Januarythe FDA approved vilazodone hydrochloride Viibryd for the treatment of MDD in adults. Its mechanism of action is not fully understood but is thought to be related to its enhancement of serotonergic activity in the central nervous system through selective inhibition of serotonin reuptake.
The most common side effects are diarrhea, nausea, vomiting, sexual dysfunction, and insomnia. The medication should not be used with MAOIs due to risk of serious, sometimes fatal, drug interactions with serotonergic drugs.
SNRIs, which include venlafaxine, duloxetine, and desvenlafaxine, inhibit reuptake of serotonin and norepinephrine. They are effective in patients who do not respond to standard antidepressants or in specific patients, such as those with chronic pain e. Side effects of SNRIs are similar to that of SSRIs.
Patients should immediately contact their physician if they experience any signs of liver damage, such as itching, dark urine, yellowing jaundice of skin and eyes, fatigue, and elevated liver function tests.
Elevated blood pressure has occurred with venlafaxine and desvenlafaxine. MAOIs include phenelzine, isocarboxazid, tranylcypromine, and selegiline. They irreversibly inhibit monoamine oxidase MAOwhich results in an increase of norepinephrine and serotonin for the life of the enzyme; thus, the physiological effects of most MAOIs last up to 2 to 3 weeks.
Selective MAOIs have severe side effects and require restrictive dietary rules and care to avoid serious drug interactions. The interaction of tyramine with MAOIs can bring on a hypertensive crisis a sharp increase in blood pressure that can lead to a stroke.
Studies have measured the tyramine content of food and determined that less than 6 mg per serving is generally safe. MAOIs interact with a number of other drugs, leading to potentially life-threatening events, and should not be taken with the following agents: amphetamines, appetite suppressants, asthma inhalers, buspirone, carbamazepine, cyclobenzaprine, decongestants, dextromethorphan, dopamine, ephedrine, epinephrine, guanethidine, levodopa, meperidine, methyl-dopa, methylphenidate, other antidepressants, reserpine, stimulants, and tryptophan.
In such cases, severe high blood pressure or dangerous reactions can occur. It is important that patients discuss any other medications they are taking or plan on taking with their physician or pharmacist. Common side effects of MAOIs include orthostatic hypotension, drowsiness, dizziness, insomnia, and sexual dysfunction.
MAOIs can also cause birth defects and should not be taken by pregnant women. Drugs commonly listed in this group include amitriptyline, nortriptyline, imipramine, desipramine, doxepin, and protriptyline. TCAs inhibit the reuptake of serotonin and norepinephrine at the synaptic cleft.
These agents were among the first antidepressants in clinical use. They tend to cause heart rhythm disturbances for patients with certain heart diseases. Doses three to five times greater than therapeutic doses have caused toxic levels, leading to prolongation of the QT interval and eventual arrhythmias.
In particular, desipramine has been associated with heart rhythm abnormalities in patients who have a family history of these problems. Care should be taken when these medications are prescribed to the elderly and to those at risk of overdose or suicide.
Common side effects involve anticholinergic and orthostatic effects and include dry mouth, constipation, blurred vision, sexual dysfunction, weight gain, difficulty urinating especially in patients with benign prostatic hyperplasiadrowsiness, dizziness, and orthostatic hypotension.
Protriptyline can cause sun sensitivity. A number of patients discontinue their drugs due to side effects, even more so than those taking SSRIs or MAOIs. Mirtazapine: This drug enhances central noradrenergic and serotonergic activity and acts as an antagonist at central presynaptic alpha 2 -adrenergic inhibitory autoreceptors and heteroreceptors.
Bupropion: This drug works by inhibiting the reuptake of dopamine, serotonin, and norepinephrine, an action that results in transmission of messages to other nerves.
Bupropion causes less sexual dysfunction than SSRIs. Side effects include restlessness, agitation, sleeplessness, headache, and stomach pain. Bupropion has a risk for seizures, which increases with higher doses.
High doses may also cause dangerous heart arrhythmias. Atypical antipsychotics are drugs that are usually prescribed for schizophrenia or bipolar disorder, but they can also play a role in the treatment of severe depression.
The extract from St. The trial found that St. Patients should be encouraged to continue to take their medications regularly as directed, even if their symptoms are less noticeable or have resolved. Symptoms usually improve anywhere from 2 to 8 weeks from beginning therapy, and patients may think they no longer need the medication, or they may think it is not helping at all.
Once the person is feeling better, it is important to continue the drug for an extended period of time to prevent a relapse into depression. Some agents must be stopped gradually to normalize neurotransmitter levels and prevent rebound reactions. Patients should be encouraged to never discontinue their medication or take any new prescription or nonprescription drug or herbal remedies without first talking to their health care provider.
Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior.
Families and caregivers should be advised of the need for close observation and communication with the prescriber. Barlow DH. Abnormal Psychology: An Integrative Approach. Belmont, CA: Thomson Wadsworth; Kessler RC, Chiu WT, Demler O, et al.
Prevalence, severity, and comorbidity of month DSM-IV disorders in the National Comorbidity Survey replication. Arch Gen Psychiatry. The World Health Organization.
Annex Table 3: Burden of disease in DALYs by cause, sex, and mortality stratum in WHO regions, estimates for In: The World Health Report Changing History. Geneva, Switzerland: WHO; Major depressive disorder. American Medical Network, Inc. Accessed October 5, Kessler RC, Berglund P, Demler O, et al; National Comorbidity Survey Replication.
The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication NCS-R. Depression in boys and adolescent males. National Institute of Mental Health. NIH Pub. Revised American Psychiatric Association.
: Antidepressant for major depressive disorder| Related Content | Therefore, the person can be misdiagnosed with unipolar depression and be given Strategies to manage blood sugar through exercise. Fro AD, Antidepressqnt RJ, Bremner J, Heiser JF, Depressice M, Adaptogen anxiety relieving supplements CS, et al. International Clinical Psychopharmacology. American Psychiatric Association. Papakonstantinou T, Nikolakopoulou A, Higgins JPT, Egger M, Salanti G. American Psychiatric Association a. This is probably the lower bound, and the level of heritability is likely to be substantially higher for reliably diagnosed major depression or for subtypes such as recurrent major depression. |
| Introduction | Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction". Hochstrasser B, Isaksen PM, Koponen H, Lauritzen L, Mahnert FA, Rouillon F, et al. For example, your doctor may do a blood test called a complete blood count or test your thyroid to make sure it's functioning properly. But in addition to professional treatment, these self-care steps can help:. The preexisting vulnerability can be either genetic , [36] [37] implying an interaction between nature and nurture , or schematic , resulting from views of the world learned in childhood. An exploration of the status of the serotonin theory of depression in the scientific literature". |
| Pharmacotherapy of Major Depressive Disorder | The APA Antideprressant antidepressant depreessive as an initial disordfr choice in people with Antidepressant for major depressive disorder, moderate, or severe major depression, and that should be given to Athletic performance beverage people with severe depression Metabolic fat burning ECT is planned. Xisorder particular, desipramine has been associated with heart rhythm abnormalities in patients who have a family history of these problems. Netherlands: In the Netherlands, paroxetine is the most prescribed antidepressant, followed by amitriptylinecitalopram and venlafaxine. A randomized controlled trial evaluated the rapid antidepressant effects of the psychedelic Ayahuasca in treatment-resistant depression with a positive outcome. Int J Neuropsychopharmacol. nature molecular psychiatry systematic review article. Seroquel XR quetiapine fumarate package insert. |
| Pharmacotherapy of Major Depressive Disorder | When choosing an antidepressant that's likely to work well for you, your health care provider may consider:. Bai Z, Luo S, Zhang L, et al. Other aspects of the initial treatment of depression are discussed separately, as are continuation and maintenance treatment of major depression, the treatment of resistant depression, and the clinical manifestations and diagnosis of depression. McCullough ME, Larson DB. There are many specific types of psychotherapy that are used to treat depression. |
| Gellatly J, Bower Optimal fat-burning potential, Hennessy S, et al. Journal of Cardiovascular Medicine. He disoder that objective loss, such Antidepressant for major depressive disorder the loss Antidepresssant Metabolic fat burning valued relationship through death or a romantic break-up, results in subjective loss as well; the depressed individual has identified with the object of affection through an unconsciousnarcissistic process called the libidinal cathexis of the ego. Acta Psychiatr Scand. Pervasive Specific. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. |
Nach meiner Meinung irren Sie sich. Geben Sie wir werden besprechen. Schreiben Sie mir in PM.